LASA SUPERGENERICS
|
The Current P/E Ratio of LASA SUPERGENERICS is -5.97.
Share Price | ₹25.5 | Apr 25,2024 |
Market Cap | ₹127.9 Cr | |
Earnings-TTM | ₹-21.4 Cr | TTM-Standalone Results |
Price/Earnings | -5.97x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of LASA SUPERGENERICS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹127.9 Cr] as on Apr 25,2024
(/) Earnings [ ₹-21.4 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -5.97x ]
Thus, for LASA SUPERGENERICS , the investors are currently willing to pay -5.97 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LASA SUPERGENERICS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LASA SUPERGENERICS over the last five years.
Historical PE (Price/Earnings) ratio chart of LASA SUPERGENERICS
PE Ratio Performance Analysis for LASA SUPERGENERICS
- LASA SUPERGENERICS 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 8.51x.
- LASA SUPERGENERICS 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LASA SUPERGENERICS 's p/e ratio peaked in Mar2020 at 31.83x.
- LASA SUPERGENERICS 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does LASA SUPERGENERICS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
LASA SUPERGENERICS | -21.43 | -5.97 | 127.9 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8,998.63 | 40.54 | 364,831.0 |
CIPLA LTD | 3,744.03 | 30.31 | 113,471.0 |
DR REDDYS LABORATORIES LTD | 5,209.40 | 19.91 | 103,713.0 |
ZYDUS LIFESCIENCES LTD | 2,954.20 | 32.39 | 95,687.8 |
DIVIS LABORATORIES LTD | 1,382.97 | 73.73 | 101,960.0 |
MANKIND PHARMA LTD | 1,743.30 | 55.12 | 96,093.1 |
TORRENT PHARMACEUTICALS LTD | 1,494.00 | 60.99 | 91,124.7 |
LUPIN LTD | 1,809.74 | 40.16 | 72,687.6 |
AUROBINDO PHARMA LTD | 2,777.89 | 23.28 | 64,661.3 |
ABBOTT INDIA LTD | 1,145.58 | 47.60 | 54,533.1 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LASA SUPERGENERICS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | -5.97x |
Max industry PE | 73.73x |
Median industry PE | 40.16x |
Average industry PE | 38.01x |
You may also like the below Video Courses